Navigation Links
Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
Date:7/31/2008

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will release financial results for the three and six months ended June 30, 2008 before market open on Friday, August 8, 2008.

Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost, PhD, Vice President and Chief Scientific Officer, Robert Little, Vice President and Chief Commercial Officer, David Ramsay, Vice President and Chief Financial Officer, and Robert Uhl, Senior Director, Investor Relations, will host an investment community conference call beginning at 8:00 a.m. PT (11:00 a.m. ET) on Friday, August 8, 2008, to provide a pipeline update.

Individuals interested in participating in the conference call may do so by dialing 888-256-9044 for domestic callers or 706-643-5585 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the Company's web site at http://www.halozyme.com. A replay will be available on Halozyme's web site for 30 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation code 57745069.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the f
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Halozyme Therapeutics Added to Nasdaq Biotech Index
2. Prime Therapeutics Receives TIPPS Certification
3. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
4. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
5. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
6. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
7. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Most mommy blogs are simple family journals, ... to attract all mothers from all walks of life. ... whether its high fashion or child rearing. When Felicia ... the Internet was so segmented. “I found myself visiting ... and then search Google to get information on another. ...
(Date:7/31/2014)... and saliva tests that help accurately predict recurrences of ... The tests screen for DNA fragments of the human ... mouth or other parts of the body. A description ... issue of JAMA Otolaryngology Head & Neck ... in the year after initial therapy to take an ...
(Date:7/31/2014)... 31, 2014 LDM Global ( http://www.ldmglobal.com ... model that is simplified and predictable with fixed fees ... As a leading international provider of legal discovery management ... has become glaringly apparent that both the courts and ... budgets and the complex pricing structure that plagues the ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, ... don,t see themselves that way, which makes achieving a ... new study, 27 percent of children and teens underestimated ... 25 percent of parents underestimated their child,s weight and ... "Efforts to prevent childhood obesity should incorporate education ...
(Date:7/31/2014)... ROCHESTER, Minn. Implementation of an algorithm aimed ... the utilization of computed tomography (CT) scans, without ... have found. The study was recently published in ... is the most common cause of acute abdominal ... becomes inflamed and filled with pus. CT scans ...
Breaking Medicine News(10 mins):Health News:Mommylish Launches Its Website 2Health News:Blood and saliva tests help predict return of HPV-linked oral cancers 2Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 3
... , , Magnifies financial and ... impact services and cost to consumers , , ... the proposed Senate health care plan , America,s ... requirements applicable to nonprofit hospitals starting in 2010. According to the ...
... , WASHINGTON, Sept. 16 Today U.S. Sen. ... Health Future Act of 2009" that will be marked-up in ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , ... subsidize health plans that cover all elective abortions and moves ...
... Researchers suggest strong disapproval of contraception might be a ... birth rates are higher in states with greater levels ... contraception, a new U.S. study suggests. , In the ... Prevention data on teen birth rates with data from ...
... 20-year follow-up study revealed a dramatic drop in liver cancer ... hepatitis B virus at birth, according to a study published ... Cancer Institute . In July 1984, a universal vaccination ... the hepatitis B virus infection, which can predispose to the ...
... , NEW YORK, Sept. 16 The Nielsen ... CLIO Awards, one of the world,s most recognized international advertising and design ... first-ever CLIO Healthcare Awards to be held on ... contemporary, modern space near Highline Park, befitting an innovative awards show. ...
... , ROCHESTER, Minn., Sept. 16 Here ... HealthSource . You may cite this publication as often as you ... is required. Reprinting is allowed for a fee. Include the ... www.bookstore.mayoclinic.com or call toll-free for subscription information, 800-876-8633, extension ...
Cached Medicine News:Health News:Baucus Bill Imposes Additional Tax Burdens on Nonprofit Hospitals 2Health News:Family Research Council: Senator Baucus Undermines President Obama's Abortion Funding Claim 2Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Mixer on November 13th at Skyline Studios NYC 2Health News:Nielsen Announces First-Ever CLIO Healthcare Awards Mixer on November 13th at Skyline Studios NYC 3Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 2Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 3Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 4Health News:September 2009 Mayo Clinic Women's HealthSource Highlights Ovarian Cancer, Salt and Breaking a Sweat 5
(Date:7/31/2014)... Nektar Therapeutics (Nasdaq: NKTR ) today ... 30, 2014. Cash and investments in marketable ... to $309.1 million at March 31, 2014."The second half of ... look forward to significant milestones for a number of our ... Executive Officer of Nektar. "The first of these is the ...
(Date:7/31/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... announced that the Company will release results for the ... before the opening of the U.S. financial markets. The ... at 8:30 a.m. ET to discuss results and highlights ... to be used during the call will be available ...
(Date:7/31/2014)... SARASOTA, Fla. , July 31, 2014 ... announced today that it has initiated the development of ... ; and that it has selected Quotient Clinical, ... United Kingdom (UK) to run its early ... a Clinical Trial Application (CTA) by the end of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... YORK, March 7, 2012  The Alzheimer,s Drug Discovery ... (AFTD) announced today the recipients of their fifth ... Program.   The goal of the ... therapies for frontotemporal degeneration (FTD).  ...
... OAKS, Calif., March 7, 2012  Amgen Inc. ("Amgen") (NASDAQ: ... offering period of the tender offer (the "Offer") by a ... of common stock of Micromet, Inc. ("Micromet") (NASDAQ: ... offering period expired at 12:00 midnight, New York City time, ...
Cached Medicine Technology:Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 2Awards for Drug Discovery Research for Frontotemporal Degeneration Announced 3Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 2Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 3Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc. 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: